Be sure to check out our detailed stock analysis (click here). Boston Scientific (NYSE: BSX) has rallied nicely year to date, up over 35%, but is there still room to grow for this heart-related devices company? Cardiovascular disease remains the number one killer worldwide. The number of adults diagnosed with heart disease in the U.S. is around 11.8 percent of the total population.
Earlier this year Boston revised growth plans to better account for the challenging economic environment. Boston has announced plans to focus on strategic initiatives like restructuring and movement toward emerging markets, both big positives.